Group items matching

in title, tags, annotations or url

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

The NHS is facing a range of long term challenges which needs to be countered with prevention, enhance personalised care and sustainable performance, health and social care secretary Sajid Javid said on Tuesday (March 8). In his speech on healthcare reform at the Royal College of Physicians in London, he said: "We face some long-term challenges: how to keep the NHS focused on delivery while futureproofing it for changing demographics and disease; how to meet rising patient expectations and address the injustices of widespread disparities; and how to deal with an unsustainable financial trajectory while backing the brilliant people who work in health and care." Javid emphasised on three key points for healthcare reform - prevention, personalisation and performance. He said, prevention is not just about building a 'national hospital service' but a true 'National Health Service'.

The summer sun can be tough on your skin, but following these amazing tips will help keep your skin healthy all season long! Drink plenty of water to stay hydrated, wear sunscreen religiously, and don't forget to exfoliate regularly to slough away dead skin cells. If you start to experience any skin problems, consult a dermatologist immediately. With these tips, you'll have gorgeous, healthy skin all summer long! 1. DRINK PLENTY OF WATER Staying hydrated is crucial for healthy skin, especially during the summer when the weather is hot and humid. Drink at least eight glasses of water per day to keep your skin looking its best. We spoke with For Care Education and Research and they said that water is the primary nutrient that helps all organs in the body function. Drinking enough water each day is essential to maintaining healthy skin. Additionally, be sure to avoid dehydration by drinking sports drinks or juices when participating in outdoor activities. It's important to replace the fluids and electrolytes your body is losing when you sweat. 2. WEAR SUNSCREEN You should be wearing sunscreen every day, regardless of the season, but it's especially important during the summer. The sun's rays are strongest then and can do serious damage to your skin if you're not careful. Look for a sunscreen with an SPF of at least 30 that provides broad-spectrum protection from both UVA and UVB rays. Apply it generously to all exposed areas of skin, including your face, neck, chest, and hands. Reapply every two hours or more often if you're sweating or swimming. This will help protect your skin from premature aging, sunburns, and other harmful effects of the sun.

The result from the Royal Pharmaceutical Society (RPS)'s survey showed that pharmacists witnessed 'the cost of living is having an impact on whether people can afford prescription medicines in England'. RPS has long campaigned to remove prescription charges for people with long-term conditions in England because they create a financial barrier to patients receiving the medicines needed to keep them well. The charge currently stands at £9.35 per item prescrib9ed and an annual rise usually occurs in April. Prescriptions are free for people in Scotland, Wales and Northern Ireland. One in two pharmacists who responded to the survey said they've seen an increase in the last six months in patients asking them which medicines on their prescription they can 'do without' due to affordability issues. One in two pharmacists had seen a rise in people not collecting their prescription, whilst two out of three pharmacists reported an increase in being asked if there was a cheaper, over-the-counter substitute for the medicine they had been prescribed.

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

Recently, the English Health Secretary has talked about introducing a 'Pharmacy First' model similar to that which exists in Scotland. This would be a win-win outcome providing people with better access to essential healthcare support, advice and treatment whilst relieving strain on other parts of the NHS, not least GPs and A&E. It is a no-brainer and yet despite a few media headlines there are still no firm proposals on the table to make this a reality. It surely cannot be right that you can receive a broad range of patient care services in Scotland which are not available in England. It works well in Scotland, Wales is keen to develop more pharmacy-based services and Northern Ireland, leaving aside the current funding dispute, has had a minor ailments service for many years. If the English Health Secretary is sincere in his interest in adopting an English version of the Scottish model, then there are critical aspects he needs to consider. Firstly, start with the patient journey through the healthcare ecosystem from illness prevention through to long-term condition management. What is the role of community pharmacy and how do we guide people to seek support from the most appropriate healthcare professional? What is the vision for community pharmacy delivering patient care in the next decade? The lesson from Scotland is that the government needs to sit down with the sector and map that out together. There are no quick fix overnight solutions. This needs to be a long-term commitment backed by adequate funding. Supervision regulations need to change and there needs to be a thought through workforce strategy which avoids community pharmacy shortages as that does nothing to deliver improved patient outcomes.

Responding to a new National Audit Office (NAO) report that indicated that NHS England's Long Term Workforce Plan (LTWP) needs improvements, the Royal College of General Practitioners (RCGP) has expressed concerns that the plan may not adequately address the needs of GPs. Published in June 2023, the workforce plan estimated that the NHS's health workforce will need to grow from 1.4m full-time equivalent (FTE) staff in 2021-22 to between 2.3m and 2.4m FTE workers in 2036-37, an increase of 65 per cent to 72 per cent. However, the NAO report highlighted that the workforce modelling has significant weaknesses, including a complex design; manual adjustments; optimistic future assumptions and limited public communication of their uncertainty; and modelling outputs that could not be fully replicated. To improve the modelling, the report recommended exploring the uncertainty of these assumptions and considering potential outcomes if they do not materialize as expected. Additionally, it suggested including full integration of the different parts of the modelling pipeline to minimise manual adjustments.

Community Pharmacy England (CPE) highlighted the untapped potential of community pharmacies in the prevention and management of long-term conditions to Conservative MPs during an event last week. The roundtable discussion was attended by a select group of influential and supportive MPs alongside community pharmacy owners, the Chief Executive of Community Pharmacy England, the Director of NHS Services, and patient representative group Healthwatch. MPs in attendance included Steve Double, MP for St Austell and Newquay, who chaired the discussion; Will Quince MP, former Minister for Pharmacy, Derek Thomas MP, Sir Peter Bottomley and Peter Aldous MP. They talked about the current pressures and funding crisis in community pharmacy, exploring solutions on how this could be eased and the huge benefits that can be unlocked.

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use. It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient." Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions. Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed. Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.

Despite being more connected than ever, the majority of Europeans are experiencing feelings of loneliness. The STADA Health Report 2024, released on Monday, revealed that over half (52 per cent) of Europeans "always, often or occasionally" feel lonely. Although the younger generation reports the highest levels of overall happiness, they are the ones most affected by this current loneliness epidemic. Nearly two-thirds (63 per cent) of Europeans aged 18 to 35 reported feeling lonely, compared to 41 percent of those aged 55 and older - according to the report, based on a survey of over 46,000 respondents aged 18 to 99 across 32 countries. Extensive screen time is contributing to increased loneliness among younger people. Europeans under the age of 34 are much more likely to spend long hours on their devices (41 per cent) than those aged 35-54 (22 per cent) and those over 55 (13 per cent). The survey found that people who spend a "long" or "fair" amount of time on social media were significantly more prone to feelings of loneliness compared to those who restrict their screen time. Moreover, extensive screen time was also associated with more intense feelings of loneliness.

Expressing apprehension over the concerning decline in the nursing workforce, Sir Julian Hartley, CEO of NHS Providers, urged the forthcoming government to bolster investment in nursing education and enhance support for student nurses. Recent analysis from the Royal College of Nursing (RCN) has projected that the NHS Long Term Workforce Plan will fall short by 10,000 new nurses by 2025. Commenting on the RCN analysis, Sir Hartley underscored the critical importance of having an adequate number of nurses to ensure the delivery of safe, high-quality patient care. "Without enough nurses, the delivery of safe, high-quality patient care is compromised," he said. He cautioned that the predicted shortfall in nurses would exacerbate existing pressures on the NHS, resulting in Long waiting times, delayed treatments and staff burnout.

Tynor Wrist Brace with Thumb Wrist brace with thumb is designed to support, protect and partially immobilize the wrist and the palm while allowing free and natural movement of the fingers. It compresses the area and retains the body heat to allay local pain and inflammation. Extra grip. Extra porous Controlled compression. Anatomical thumb placement. Tynor Wrist Brace with Thumb Features High quality , striped elastic webbing Strong and durable Porous and comfortable High modulus of elasticity- Retains shape and size for a long time. Excellent compressive strength, better support Hook loop closures Easy to apply and remove Ensures optimal compression Better fitting and universal sizing. Anatomical thumb opening Better pain relief and healing. Thumb in abduction remains relaxed, no fatigue Improves comfort Allows free and natural movement of the thumb and fingers.

Krishna Eye and Ent Hospital specialised in vision test. We offer refractive surgery and vision test for myopia, short sight, long site, hypermetropia, shortsightedness and farsightedness.

Powerchairs are generally four-wheeled or six-wheeled and non-folding, however some folding designs exist and other designs may have some ability to partially dismantle for transit. Four general styles of powerchair drive systems exist: front, centre or rear wheel drive and all-wheel drive. Powered wheels are typically somewhat larger than the trailing/castoring wheels, while castoring wheels are typically larger than the castors on a manual chair. Centre wheel drive powerchairs have castors at both front and rear for a six-wheel layout. Angel Wheelchair Electric standing wheelchair Standing up, driving function by power. Head and signal light (controlled by joystick). Adjustable headrest. Adjustable footplate. Detachable backrest Rigid steel framework W/liquid coating Flip-backward armrest Max speed: 9.15KM/H Front castor: 2.80/2.50-4 pneumatic castor (9") Rear wheels: 3.00-8 pneumatic tire (14") Available seat width: A (46 cm), D (42 cm) Max loading: A size: 135 kg Net weight w/o battery: 62.7 kg A powerchairs is a wheelchair that is propelled by means of an electric motor rather than manual power. Power wheelchairs are useful for those unable to propel a manual wheelchair or who may need to use a wheelchair for distances or over terrain which would be fatiguing in a manual wheelchair. They may also be used not just by people with 'traditional' mobility impairments, but also by people with cardiovascular and fatigue based condition. An powerwheelchair powers more than just chair. It gives the power to safely travel long distances on own. It empowers to navigate through home, backyard, school, workplace or local park. It gives power to do the things,want to do. It gives power. When accidents occur that leave permanent leg injuries, or as age sets in and joint pain becomes unbearable, the power chair acts as a gateway to continue living life to the fullest. The powerwheelchairs in our lineup are all battery powered, yet each device fills

GM LITE POWER WHEELCHAIR GM Lite Brushless Power Wheelchair with Batteries is a revolutionary light weight power wheelchair using brushless motor. It is the most economic power wheelchair without sacrificing safety & durability. The wheelchair promotes pressure redistribution, reduces downward sliding and helps maintain good posture. Specifications: 10 times longer life Lightest - 23 kg 5 year long life, safe LiFePO4 battery (10ah) High efficiency brushless hub motor 5 seconds folding and unfolding Easy to carry Load : 120 kg Speed : 8km/hr Range: 15 km Slope : 12% 24V180W brushless 8-inch gear hub motor

Black pepper is used in almost every recipe. It has long been known for the treatment of formation of intestinal gas. It also include respiratory disease, cough, common cold etc.

Black pepper is used in almost every recipe. It has long been known for the treatment of formation of intestinal gas. It also include respiratory disease, cough, common cold etc.

Tynor Chest Binder Chest Binder is applied to the thoracic region to compress and bind the rib cage and provide splinting to the sternum while allowing sufficient flexibility for comfortable breathing. Anatomic chest pad. Controlled compression. Optimum chest splinting. Soft feel. Tynor Chest Binder Features 50 mm thick PUF pad hold and binds the fractured sternum without compromising on patient comfort. Strong elastic band gives good grip and helps in equidistribution of pressure. Reduces post operative pain and discomfiture. Facilitates phlegm expulsion after cardio thoracic surgery. Tynor Chest Binder Measurements Measure circumference around the chest.

The main cause of hair loss in the female is hormonal and genetic. Other causes are various vitamin, nutrient, protein and iron deficiency. Females usually ignore about their diet and often takes meals at long interval reason they take care of entire family and do not pay attention to themselves. So poor diet, stress, and hormones abnormalities are the most common cause of hair loss in females.

The main cause of hair loss in the female is hormonal and genetic. Other causes are various vitamin, nutrient, protein and iron deficiency. Females usually ignore about their diet and often takes meals at long interval reason they take care of entire family and do not pay attention to themselves. So poor diet, stress, and hormones abnormalities are the most common cause of hair loss in females.

Since the introduction of the 2019 NHS Long-Term Plan, several policy commitments have surfaced, presenting a definitive 'blueprint' for community pharmacy in England. The Company Chemists Association has identified four crucial commitments that, when integrated, hold the potential to revolutionise patient care through community pharmacies. "Each commitment is like a crucial piece of a puzzle," CCA said. "For the transformation of patient access through community pharmacy to be successful, all these pieces must come together harmoniously. Otherwise, the picture will remain incomplete." The four major pieces of the puzzle coined by CCA include: * Building on education and training reforms to increase the size and capability of the workforce. * Expanding the number of clinical services commissioned and delivered in community pharmacy. * Introducing digital enablers which underpin service delivery. * Introducing legislative changes to increase capacity and allow the delivery of more patient-facing clinical care.

The Pharmacists Defence Association (PDA) has expressed its keenness to work with the NHS nationally and at the ICB level to discuss how the pharmacist workforce can most effectively be part of the multidisciplinary team, after the publication of Long-awaited NHS England workforce plan. Welcoming its publication Alison Jones, PDA Director of Policy said: "It gives greater clarity around the future direction and strategy for professional development, training, and opportunities for those currently working in the health service or considering their future career. There is a strong emphasis on further development of the clinical role of pharmacists to support better patient care. "However, this is a plan that will take years, indeed decades to come to fruition and its success will need to be underpinned by significant funding for its entire life course. Workplace pressures, reductions in support staff, and a lack of protected learning time are matters of immediate concern for many PDA members, issues which are regularly highlighted through activities, such as the safer pharmacies survey.